If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Humulin®
- Full Prescribing Information
Humulin® R (U-100) (regular insulin human injection, USP [rDNA origin])
100 units/mL - Full Prescribing Information
Humulin® R (U-500) (regular U-500 [concentrated] insulin human injection, USP [rDNA origin])
500 units/mL - Full Prescribing Information
Humulin® 70/30 (70% human insulin isophane suspension and 30% human insulin injection [rDNA origin])
100 units/mL - Full Prescribing Information
Humulin® N U-100 (human insulin [rDNA origin] isophane suspension)
100 units/mL
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
CONNECTED CARE: Timelines
While this is one of our priorities, Eli Lilly and company does not speculate about approval and launch timelines.
Lilly is working to develop the Connected Care technologies for patients with diabetes. As with any such effort, pharmaceutical product, or medical device, there are substantial risks and uncertainties in the process of development and commercialization.
There is no guarantee that these platforms will be approved by the FDA, commercially successful, or that the company will meet its anticipated timelines for the rollout of these platforms. While this is one of our priorities, Lilly does not speculate about approval and launch timelines.
Glossary
DM = diabetes mellitus
FDA = Food and Drug Administration
Lilly = Eli Lilly and Company
Date of Last Review: November 22, 2019
Contact Lilly
Call Us
If you need information about a Lilly product or want to report an Adverse Event or Product Complaint, you may call us.
Available Mon - Fri, 9am - 7pm EST
